Comparison 3. Ivermectin compared to no treatment for prevention of SARS‐CoV‐2 infection.

Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
3.1 Development of clinical COVID‐19 symptoms (secondary analysis)	1	304	Risk Ratio (M‐H, Random, 95% CI)	0.13 [0.08, 0.21]
3.2 Any adverse events within 14 days (secondary analysis)	1	304	Risk Ratio (M‐H, Random, 95% CI)	11.50 [0.68, 193.21]
3.3 All‐cause mortality up to 28 days (primary analysis)	1	304	Risk Ratio (M‐H, Random, 95% CI)	Not estimable